MabTrix

What MabTrix does

MabTrix is a privately held, for-profit biopharmaceutical company founded in 2015 and headquartered in Ness Ziona, Israel. The company name and the short firmographic description indicate an antibody-based therapeutics focus, consistent with a developer of biologic drugs typically targeting oncology, immunology, or related disease areas. The company is a portfolio company of FutuRx, an Israeli biotechnology incubator known for providing early-stage lab infrastructure, seed capital, and operational support to nascent therapeutic ventures. The company is led by Chief Executive Officer Dorit Landstein.

The company's website (https://www.futurx.co.il/portfolio/mabtrix/) is currently displaying a default cPanel error page rather than active corporate content, and no detailed product pipeline, technology platform, indications, partnership data, or clinical-stage programs are documented in the available input. This means specifics on targets, modalities, discovery platform architecture, or development stage cannot be verified from the supplied material. No customer base, pricing model, go-to-market motion, or revenue mechanics are disclosed, which is consistent with a pre-commercial, research-stage biopharmaceutical company that has not yet out-licensed or commercialized a product.

Based on the absence of any disclosed product launches, partnerships, regulatory filings, or commercial transactions, MabTrix appears to be operating at a preclinical or early-discovery stage, with its value proposition resting on proprietary antibody research and development rather than on near-term revenue generation. Investment-relevant inferences about pipeline value, capital efficiency, and exit potential cannot be made from the available data, and any deeper analysis would require access to non-public scientific, financial, or investor materials.

Name

MabTrix

Website

https://futurx.co.il

Company type

Private

Founded year

2014

Headcount range

11–50 employees

Short description

MabTrix is a privately held Israeli biopharmaceutical company founded in 2015 in Ness Ziona, focused on antibody-based therapeutic development and backed by the FutuRx biotech incubator.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro industry

PRIMARYHLAAAAAA

Monoclonal Antibody Therapeutics (mAbs)

Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

• Antibody therapeutics
• Biopharmaceutical development
• Monoclonal antibodies
• Drug discovery
• Biotech research

Headquarters

HQ city

Ness Ziona

HQ country

Israel

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

MabTrix is a biopharmaceutical company developing therapeutic antibody-based products. The company name (MabTrix) suggests a focus on monoclonal antibody (mAb) therapeutics, a core modality in modern biopharma. Specific pipeline products, target indications, and technology platforms are not detailed in the available source material.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Expansion highlights1 record

Broad incumbents

• Genmab: Major publicly-traded mAb therapeutics company with a broad portfolio of approved and clinical-stage antibodies. Comparable as a pure-play mAb developer and natural strategic acquirer of early-stage antibody assets.

Direct peers

• MacroGenics: Clinical-stage biopharmaceutical developing multiple monoclonal antibody therapeutics across oncology and autoimmune indications. Comparable as a direct peer in therapeutic mAb development.

Emerging players

• Adagene: Clinical-stage biopharmaceutical developing antibody-based therapeutics using computational and synthetic biology approaches. Comparable as an emerging mAb developer targeting oncology and immunology.
• AbCellera: Technology-enabled antibody discovery platform partnering with pharma to advance mAb candidates. Comparable as an emerging mAb-focused company leveraging discovery platforms and pharma partnerships.

Regional players

• BioLineRx: Israeli clinical-stage biopharmaceutical developing multiple therapeutic candidates, including biologics. Comparable as a fellow Israeli biotech operating from the same regional ecosystem.
• Compugen: Israel-based clinical-stage biopharmaceutical developing computational-discovered antibody-based therapeutics. Directly comparable to MabTrix as an Israeli biologics developer in the mAb space.
• RedHill Biopharma: Israeli specialty biopharmaceutical company focused on late-clinical-stage therapeutics. Comparable as a Tel Aviv-area biopharma with similar operational structure, though focused on small molecules rather than mAbs.
• Galmed Pharmaceuticals: Israel-based clinical-stage biopharmaceutical with operations near Tel Aviv. Comparable as another Israeli biopharma navigating capital markets and clinical development.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/futurx

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MabTrix